research use only
Cat.No.S8851
| Related Targets | CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel ATPase GluR |
|---|---|
| Other CFTR Inhibitors | Tezacaftor (VX-661) Vanzacaftor (VX-121) CFTRinh-172 GLPG1837 FDL169 Galicaftor (ABBV-2222) GlyH-101 IOWH032 PPQ-102 Nesolicaftor (PTI-428) |
|
In vitro |
DMSO
: 100 mg/mL
(167.32 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 597.65 | Formula | C26H34F3N7O4S |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 2216712-66-0 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC1CC(N(C1)C2=C(C=CC(=N2)N3C=CC(=N3)OCC(C)(C)C(F)(F)F)C(=O)NS(=O)(=O)C4=CN(N=C4C)C)(C)C | ||
| Targets/IC50/Ki |
CFTR
|
|---|---|
| In vitro |
The pendrin-dependent increase in cystic fibrosis transmembrane conductance regulator (CFTR) current is additive with the CFTR modulator elexacaftor. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06331000 | Not yet recruiting | Cystic Fibrosis |
University Hospital Strasbourg France |
March 2024 | -- |
| NCT05519020 | Recruiting | Cystic Fibrosis |
Sheffield Teaching Hospitals NHS Foundation Trust |
July 27 2022 | -- |
| NCT03525548 | Completed | Cystic Fibrosis |
Vertex Pharmaceuticals Incorporated |
August 3 2018 | Phase 3 |
| NCT03525444 | Completed | Cystic Fibrosis |
Vertex Pharmaceuticals Incorporated |
June 15 2018 | Phase 3 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.